SALL4高表达预示癌症预后不良：一项荟萃分析。

Higher expression of SALL4 predicts poor cancer prognosis: A meta-analysis.

作者信息

Shen Hongyu, Li Liangpeng, Wang Dandan, Yang Sujin, Chen Xiu, Zhou Siying, Zhong Shanliang, Zhao Jianhua, Tang Jinhai

机构信息

The Fourth Clinical School of Nanjing Medical University, Nanjing 210009, Jiangsu, China.

Department of General Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, Jiangsu, China.

出版信息

Cancer Biomark. 2017 Jul 4;19(4):365-373. doi: 10.3233/CBM-160052.

DOI:10.3233/CBM-160052

PMID:28582841

Abstract

BACKGROUND

Sal-like protein 4 (SALL4) is recognized as a potential biomarker for assessing cancer prognosis. Many experiments have been done to explore the aberrant expression of SALL4 in cancer patients.

OBJECTIVE

To explore the association between SALL4 expression and cancer prognosis.

METHODS

A systematically comprehensive search was performed through PubMed, Web of Science, and CNKI. The prognostic value of SALL4 expression in cancer patients was evaluated by pooled hazard ratios (HRs) and 95% confidence intervals (CIs).

RESULTS

The overexpression of SALL4 was identified to be significantly associated with a poor prognosis in cancer patients (pooled HR: 2.02, 95% CI: 1.67-2.46). This association was also detected in digestive system neoplasms subgroup (pooled HR: 1.91, 95% CI: 1.52-2.39) and reproductive system neoplasms subgroup (pooled HR: 1.95, 95% CI: 1.17-3.26). In the geography subgroup analysis, a statistical association was confirmed in the Chinese subgroup (pooled HR: 1.982, 95% CI: 1.526-2.576). In the respect of disease progression, there was a certain degree of relationship between higher expression of SALL4 and recurrence-free survival (RFS) (pooled HR: 1.617, 95% CI: 1.190-2.196).

CONCLUSION

SALL4 is a promising prognostic biomarker for cancer, and is appropriate for the assessment of cancer prognosis in the Chinese people.

摘要

背景

Sal样蛋白4（SALL4）被认为是评估癌症预后的潜在生物标志物。已经进行了许多实验来探索SALL4在癌症患者中的异常表达。

目的

探讨SALL4表达与癌症预后之间的关联。

方法

通过PubMed、Web of Science和中国知网进行系统全面的检索。通过合并风险比（HR）和95%置信区间（CI）评估SALL4表达在癌症患者中的预后价值。

结果

SALL4的过表达被确定与癌症患者的不良预后显著相关（合并HR：2.02，95%CI：1.67-2.46）。在消化系统肿瘤亚组（合并HR：1.91，95%CI：1.52-2.39）和生殖系统肿瘤亚组（合并HR：1.95，95%CI：1.17-3.26）中也检测到这种关联。在地理亚组分析中，在中国亚组中证实了统计学关联（合并HR：1.982，95%CI：1.526-2.576）。在疾病进展方面，SALL4的高表达与无复发生存期（RFS）之间存在一定程度的关系（合并HR：1.617，95%CI：1.190-2.196）。